A retrospective study of adverse events and costs in metastatic melanoma patients treated with Ipilimumab and nivolumab
Latest Information Update: 28 Jul 2021
Price :
$35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 28 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology